Diabetes

The cost-effectiveness group say Lilly’s diabetes treatment should have an annual price of between $5,500 and $5,700. The FDA is expected to make a decision on whether to approve tirzepatide this year.

At a placeholder cost equal to Ozempic, tirzepatide scored lower in a measure of cost-effectiveness compared with Ozempic but higher than Jardiance.

FDA approval means that pharmacists can swap biosimilar Semglee, an insulin product, for brand-name Lantus, although state-level pharmacy rules may apply.

New vaccine for pneumococcal disease, an sNDA approved based on real-world data, a new therapy for skin and muscle disease, Keytruda combination receives full approval in endometrial cancer, a new diabetes therapy is approved, and another JAK inhibitor misses PDUFA date round out this week’s FDA news.

Keytruda loses one indication but gains another, Biogen narrows use of Aduhelm, Padcev gets regular approval and expanded indication, Amgen submits application for asthma biologic, agency issues complete response letter for diabetes prevention therapy teplizumab, Novartis resubmits NDA for inclisiran.

Study published in the Annals of Internal Medicine elaborates on past positive findings for Zynquista (sotagliflozin), a dual inhibitor of SGLT1 and SGLT2.

Harvard researchers say, well, maybe.

Dr. Kathleen Bethin, clinical professor, and Dr. Lucy Mastrandrea, associate professor and division chief of endocrinology/diabetes both at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo, spoke with Vic Baldry of Cecelia Health to discuss the challenges telehealth has created when caring for families with children who have type 1 diabetes.

Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.

Diabetes education has shifted from in-person classes to Zoom meetings.

Commercial health insurance plan enrollees are more likely to take glucose-lowering medications.

The findings are encouraging for future use of remote digital monitoring.

Digital health apps offer solutions to improve diabetes self-management.

Dr. Anthony Fauci addresses the American Heart Association Scientific Sessions.

After an FDA denial and a lost sponsor, sotagliflozin shows it can cut cardiovascular events and possibly treat a form of heart failure that has no approved therapies.

The findings are the first in a series of six studies involving a registry supported by drug makers in the diabetes, cardiovascular, and heart failure space.

Flu increases the risk of heart attack, especially among people with diabetes and atherosclerotic cardiovascular disease (ASCVD). COVID-19 and the possibility of co-infection makes getting vaccinated against the flu particularly important this year.

Three healthcare organizations provide models for managing the disease and keeping a close eye on the bottom line.

Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.

Results from REDUCE-IT trial presented at the ADA meeting show that the fish-oil pill is associated with cardiovascular disease protection among patients with diabetes.

Americans have been diagnosed with diabetes, mostly with the type 2 variety linked with being overweight or obese.

Several Blues plans have contracted with vendors that supply tech-enabled diabetes disease management and prevention programs. Sometimes the tech is combined with coaching - by a real, live human being.

New plan from CVS Caremark eliminates member cost as a barrier to medications without raising costs for benefits, premiums or deductibles.

A survey of diabetes educators reveals challenges faced by patients with diabetes who can’t afford their drugs.

As people with type 2 diabetes age, the risks of insulin use can outweigh its benefits, creating the need for increased provider and patient education.

Study uncovers specific areas of care that cause concern for Americans with diabetes and opportunities for developing a plan of action.

Downturn in incidence may be partially due to successful public health campaigns to prevent the disease.